TDMS Study 89029-06 Pathology Tables
NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98 Route: MAGNETIC FIELDS Time: 12:40:00 MERGED GROUPS Facility: I. I. T. Research Institute Chemical CAS #: ELECTROMAG Lock Date: 09/09/97 Cage Range: All Reasons For Removal: All Removal Date Range: All Treatment Groups: Merge 001 001,011 SHAM CONTROL Merge 002 002,012 SHAM CONTROL Merge 003 003,013 .02 GAUSS Merge 004 004,014 .02 GAUSS Merge 005 005,015 2 GAUSS Merge 006 006,016 2 GAUSS Merge 007 009,019 10 GAUSS Merge 008 010,020 10 GAUSS Merge 009 007,017 10 GAUSS INTER Merge 010 008,018 10 GAUSS INTER a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98 Route: MAGNETIC FIELDS Time: 12:40:00 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE SHAM .02 2 GAUSS 10 10 GAUSS CONTROL GAUSS GAUSS INTER ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 100 100 100 100 100 Early Deaths Natural Death 23 18 13 18 15 Moribund Sacrifice 6 7 6 7 8 Accidently Killed 1 1 2 1 Survivors Natural Death 1 Terminal Sacrifice 69 74 79 74 77 Animals Examined Microscopically 100 100 100 100 100 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Esophagus (97) (100) (99) (98) (100) Gallbladder (70) (84) (87) (79) (91) Histiocytic Sarcoma 1 (1%) 2 (2%) Rhabdomyosarcoma, Metastatic, Intestine Small, Jejunum 1 (1%) Intestine Large, Colon (82) (88) (90) (90) (93) Histiocytic Sarcoma 1 (1%) Intestine Large, Cecum (78) (87) (90) (87) (92) Histiocytic Sarcoma 1 (1%) Leiomyosarcoma 1 (1%) Serosa, Histiocytic Sarcoma 1 (1%) Intestine Small, Duodenum (77) (85) (90) (87) (91) Histiocytic Sarcoma 1 (1%) Leiomyosarcoma 1 (1%) Polyp Adenomatous 1 (1%) 1 (1%) Intestine Small, Jejunum (79) (86) (89) (91) (92) Histiocytic Sarcoma 1 (1%) Sarcoma, Metastatic, Skin 1 (1%) Serosa, Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%) Intestine Small, Ileum (78) (85) (90) (87) (93) Histiocytic Sarcoma 1 (1%) 1 (1%) Liver (98) (97) (98) (99) (100) Hemangiosarcoma 1 (1%) 1 (1%) 1 (1%) Hemangiosarcoma, Metastatic, Spleen 1 (1%) Hepatocellular Carcinoma 6 (6%) 5 (5%) 6 (6%) 6 (6%) 6 (6%) Hepatocellular Carcinoma, Multiple 1 (1%) Hepatocellular Adenoma 15 (15%) 8 (8%) 19 (19%) 17 (17%) 11 (11%) Hepatocellular Adenoma, Multiple 2 (2%) 2 (2%) 1 (1%) 1 (1%) 2 (2%) Hepatocholangiocarcinoma 1 (1%) Histiocytic Sarcoma 2 (2%) 2 (2%) 6 (6%) Page 2 NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98 Route: MAGNETIC FIELDS Time: 12:40:00 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE SHAM .02 2 GAUSS 10 10 GAUSS CONTROL GAUSS GAUSS INTER ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - cont Plasma Cell Tumor Malignant, Metastatic, Spleen 1 (1%) Plasma Cell Tumor Malignant, Metastatic, Uncertain Primary Site 2 (2%) 1 (1%) 1 (1%) Mesentery (36) (27) (30) (30) (53) Histiocytic Sarcoma 4 (8%) Leiomyosarcoma, Metastatic, Intestine Small, Duodenum 1 (3%) Liposarcoma 3 (11%) 1 (3%) 1 (2%) Osteosarcoma, Metastatic, Uncertain Primary Site 1 (2%) Plasma Cell Tumor Malignant, Metastatic, Uncertain Primary Site 1 (2%) Rhabdomyosarcoma, Metastatic, Skeletal Muscle 2 (6%) Sarcoma 1 (3%) 2 (7%) 1 (2%) Pancreas (87) (94) (96) (94) (95) Histiocytic Sarcoma 3 (3%) Rhabdomyosarcoma, Metastatic, Uncertain Primary Site 1 (1%) Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%) 1 (1%) Sarcoma, Metastatic, Mesentery 1 (1%) Sarcoma, Metastatic, Skin 1 (1%) Salivary Glands (94) (98) (97) (98) (99) Carcinoma 1 (1%) Histiocytic Sarcoma 1 (1%) 2 (2%) Stomach, Forestomach (91) (92) (93) (94) (97) Basal Cell Adenoma 1 (1%) Sarcoma 1 (1%) Squamous Cell Carcinoma 1 (1%) Squamous Cell Papilloma 1 (1%) 1 (1%) 1 (1%) Stomach, Glandular (86) (90) (93) (93) (94) Osteosarcoma, Metastatic, Uncertain Primary Site 1 (1%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Blood Vessel (98) (100) (94) (99) (96) Heart (98) (100) (100) (99) (100) Hemangiosarcoma 1 (1%) Histiocytic Sarcoma 2 (2%) Osteosarcoma, Metastatic, Bone 1 (1%) Sarcoma, Metastatic, Skin 1 (1%) ____________________________________________________________________________________________________________________________________ Page 3 NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98 Route: MAGNETIC FIELDS Time: 12:40:00 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE SHAM .02 2 GAUSS 10 10 GAUSS CONTROL GAUSS GAUSS INTER ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (92) (98) (99) (99) (99) Histiocytic Sarcoma 2 (2%) Capsule, Adenoma 2 (2%) Capsule, Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%) Capsule, Sarcoma 1 (1%) Adrenal Medulla (90) (95) (97) (97) (98) Pheochromocytoma Benign 3 (3%) 2 (2%) 2 (2%) Bilateral, Histiocytic Sarcoma 1 (1%) Bilateral, Pheochromocytoma Benign 1 (1%) Islets, Pancreatic (87) (95) (94) (94) (94) Adenoma 2 (2%) 7 (7%) 2 (2%) 3 (3%) Histiocytic Sarcoma 2 (2%) Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%) Parathyroid Gland (63) (53) (53) (53) (58) Pineal Gland (52) (37) (67) (61) (61) Histiocytic Sarcoma 2 (3%) Pituitary Gland (83) (92) (87) (89) (93) Histiocytic Sarcoma 1 (1%) Pars Distalis, Adenoma 16 (19%) 17 (18%) 18 (21%) 21 (24%) 15 (16%) Pars Distalis, Adenoma, Multiple 1 (1%) 2 (2%) 1 (1%) Pars Distalis, Histiocytic Sarcoma 1 (1%) Pars Intermedia, Adenoma 1 (1%) 1 (1%) Thyroid Gland (92) (99) (98) (98) (98) Adenoma 1 (1%) 1 (1%) 2 (2%) 1 (1%) Adenoma, Multiple 1 (1%) Histiocytic Sarcoma 1 (1%) Bilateral, Adenoma 1 (1%) C-Cell, Adenoma 1 (1%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM Peritoneum (1) Tissue NOS (1) (1) (3) Leiomyosarcoma, Metastatic, Intestine Small, Duodenum 1 (33%) Rhabdomyosarcoma 1 (100%) Sarcoma 1 (100%) 1 (33%) Schwannoma Benign 1 (33%) ____________________________________________________________________________________________________________________________________ Page 4 NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98 Route: MAGNETIC FIELDS Time: 12:40:00 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE SHAM .02 2 GAUSS 10 10 GAUSS CONTROL GAUSS GAUSS INTER ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Clitoral Gland (89) (84) (85) (84) (82) Bilateral, Histiocytic Sarcoma 1 (1%) Bilateral, Sarcoma 1 (1%) Ovary (79) (91) (95) (94) (96) Cystadenoma 3 (4%) 3 (3%) 2 (2%) 2 (2%) Granulosa Cell Tumor Benign 2 (3%) 3 (3%) 1 (1%) Hemangioma 1 (1%) 1 (1%) 2 (2%) Hemangiosarcoma 1 (1%) 1 (1%) Histiocytic Sarcoma 1 (1%) Luteoma 1 (1%) 1 (1%) Rhabdomyosarcoma, Metastatic, Intestine Small, Jejunum 1 (1%) Bilateral, Histiocytic Sarcoma 1 (1%) Bilateral, Luteoma 1 (1%) 1 (1%) Uterus (92) (97) (98) (99) (100) Hemangioma 1 (1%) Hemangiosarcoma 1 (1%) 1 (1%) Lymphangioma 1 (1%) Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%) Bilateral, Histiocytic Sarcoma 1 (1%) Cervix, Histiocytic Sarcoma 1 (1%) Endometrium, Polyp Stromal 1 (1%) 1 (1%) 1 (1%) Vagina (1) (1) Hemangiosarcoma 1 (100%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (96) (99) (97) (99) (100) Histiocytic Sarcoma 1 (1%) 1 (1%) Sarcoma 1 (1%) Lymph Node (19) (15) (4) (14) (12) Histiocytic Sarcoma 1 (8%) Sarcoma, Metastatic, Skin 1 (5%) 1 (7%) Schwannoma Malignant, Metastatic, Skin 1 (5%) Bronchial, Histiocytic Sarcoma 1 (5%) Iliac, Sarcoma, Metastatic, Skin 1 (7%) Inguinal, Histiocytic Sarcoma 1 (5%) 1 (8%) Lumbar, Histiocytic Sarcoma 2 (13%) 2 (17%) Mediastinal, Histiocytic Sarcoma 2 (11%) 1 (7%) 1 (8%) Renal, Histiocytic Sarcoma 1 (5%) 2 (13%) Lymph Node, Mandibular (84) (94) (89) (91) (92) Histiocytic Sarcoma 2 (2%) 1 (1%) 2 (2%) Lymph Node, Mesenteric (83) (88) (89) (92) (95) Histiocytic Sarcoma 2 (2%) 2 (2%) 4 (4%) Plasma Cell Tumor Malignant 1 (1%) Page 5 NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98 Route: MAGNETIC FIELDS Time: 12:40:00 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE SHAM .02 2 GAUSS 10 10 GAUSS CONTROL GAUSS GAUSS INTER ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM - cont Rhabdomyosarcoma, Metastatic, Tissue NOS 1 (1%) Rhabdomyosarcoma, Metastatic, Uncertain Primary Site 1 (1%) Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%) Spleen (91) (93) (95) (93) (99) Hemangiosarcoma 1 (1%) Histiocytic Sarcoma 2 (2%) 2 (2%) 2 (2%) 4 (4%) Plasma Cell Tumor Malignant 1 (1%) 1 (1%) 1 (1%) Thymus (78) (92) (84) (75) (89) Histiocytic Sarcoma 1 (1%) 2 (2%) 3 (3%) Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%) Sarcoma, Metastatic, Skin 1 (1%) Thymoma Benign 1 (1%) 1 (1%) Thymoma Malignant 1 (1%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (94) (98) (99) (99) (98) Adenoma 1 (1%) 2 (2%) 1 (1%) Carcinoma 1 (1%) 1 (1%) Histiocytic Sarcoma 1 (1%) Skin (99) (100) (100) (100) (100) Basal Cell Carcinoma 1 (1%) Fibrosarcoma 1 (1%) Hemangioma 1 (1%) 1 (1%) Hemangiosarcoma 1 (1%) 1 (1%) 2 (2%) Rhabdomyosarcoma, Metastatic, Uncertain Primary Site 1 (1%) Sarcoma 4 (4%) 5 (5%) 2 (2%) 3 (3%) 4 (4%) Schwannoma Malignant 2 (2%) 1 (1%) 4 (4%) 1 (1%) 2 (2%) Trichoepithelioma 1 (1%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (100) (100) (99) (99) (99) Femur, Hemangiosarcoma, Metastatic, Spleen 1 (1%) Femur, Osteosarcoma 1 (1%) Sternum, Sarcoma, Metastatic, Mesentery 1 (1%) Vertebra, Osteosarcoma 1 (1%) Skeletal Muscle (7) (3) (3) (4) (4) Hemangiosarcoma, Metastatic, Heart 1 (25%) Osteosarcoma, Metastatic, Uncertain Primary Site 1 (25%) Rhabdomyosarcoma 3 (43%) 1 (33%) 1 (25%) ____________________________________________________________________________________________________________________________________ Page 6 NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98 Route: MAGNETIC FIELDS Time: 12:40:00 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE SHAM .02 2 GAUSS 10 10 GAUSS CONTROL GAUSS GAUSS INTER ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (99) (100) (98) (98) (100) Ventricle, Hamartoma, LIPOMATOUS 1 (1%) 2 (2%) 1 (1%) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (95) (100) (99) (99) (100) Alveolar/Bronchiolar Adenoma 9 (9%) 6 (6%) 5 (5%) 6 (6%) Alveolar/Bronchiolar Carcinoma 2 (2%) 6 (6%) 2 (2%) 1 (1%) 1 (1%) Alveolar/Bronchiolar Carcinoma, Multiple 1 (1%) Basal Cell Carcinoma, Metastatic, Skin 1 (1%) Hepatocellular Carcinoma, Metastatic, Liver 2 (2%) 1 (1%) Histiocytic Sarcoma 1 (1%) 2 (2%) 2 (2%) 3 (3%) Osteosarcoma, Metastatic, Bone 1 (1%) 1 (1%) Plasma Cell Tumor Malignant, Metastatic, Uncertain Primary Site 1 (1%) Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%) Sarcoma, Metastatic, Mesentery 1 (1%) Sarcoma, Metastatic, Skin 1 (1%) 1 (1%) 1 (1%) 1 (1%) 2 (2%) Mediastinum, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (1%) Mediastinum, Histiocytic Sarcoma 1 (1%) Mediastinum, Osteosarcoma, Metastatic, Bone 1 (1%) Mediastinum, Schwannoma Malignant, Metastatic, Skin 1 (1%) Serosa, Sarcoma, Metastatic, Mesentery 1 (1%) Nose (99) (100) (99) (100) (99) Trachea (94) (100) (98) (99) (98) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Harderian Gland (98) (97) (99) (96) (97) Adenoma 9 (9%) 7 (7%) 14 (14%) 12 (13%) 12 (12%) Carcinoma 2 (2%) Histiocytic Sarcoma 1 (1%) Bilateral, Adenoma 1 (1%) 1 (1%) 1 (1%) Lacrimal Gland (1) Bilateral, Sarcoma 1 (100%) ____________________________________________________________________________________________________________________________________ Page 7 NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98 Route: MAGNETIC FIELDS Time: 12:40:00 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE SHAM .02 2 GAUSS 10 10 GAUSS CONTROL GAUSS GAUSS INTER ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (92) (96) (98) (98) (99) Histiocytic Sarcoma 1 (1%) 1 (1%) Osteosarcoma, Metastatic, Bone 1 (1%) Plasma Cell Tumor Malignant, Metastatic, Uncertain Primary Site 1 (1%) Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%) Bilateral, Histiocytic Sarcoma 1 (1%) 3 (3%) Urinary Bladder (79) (87) (94) (89) (92) Carcinoma 1 (1%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(100) *(100) *(100) *(100) *(100) Histiocytic Sarcoma 2 (2%) 2 (2%) 2 (2%) 6 (6%) Lymphoma Malignant 32 (32%) 31 (31%) 22 (22%) 26 (26%) 20 (20%) Mesothelioma Malignant 1 (1%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 8 NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98 Route: MAGNETIC FIELDS Time: 12:40:00 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE SHAM .02 2 GAUSS 10 10 GAUSS CONTROL GAUSS GAUSS INTER ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 78 80 72 71 68 Total Primary Neoplasms 132 122 124 117 110 Total Animals with Benign Neoplasms 52 49 54 49 44 Total Benign Neoplasms 68 58 77 71 61 Total Animals with Malignant Neoplasms 55 58 38 38 44 Total Malignant Neoplasms 64 64 47 46 49 Total Animals with Metastatic Neoplasms 9 8 5 5 6 Total Metastatic Neoplasm 14 21 8 8 12 Total Animals with Malignant Neoplasms 2 2 2 Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 9 NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98 Route: MAGNETIC FIELDS Time: 12:40:00 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE SHAM .02 2 GAUSS 10 10 GAUSS CONTROL GAUSS GAUSS INTER ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 100 100 100 100 100 Early Deaths Natural Death 13 15 10 24 18 Moribund Sacrifice 11 13 6 14 8 Survivors Terminal Sacrifice 76 72 84 62 73 Natural Death 1 Animals Examined Microscopically 100 100 100 100 100 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Esophagus (97) (97) (98) (96) (99) Periesophageal Tissue, Sarcoma, Metastatic, Uncertain Primary Site 1 (1%) Gallbladder (84) (83) (84) (75) (82) Adenoma 1 (1%) Carcinoma, Metastatic, Intestine Small, Duodenum 1 (1%) Intestine Large, Colon (93) (94) (92) (83) (85) Intestine Large, Rectum (93) (90) (93) (81) (87) Intestine Large, Cecum (90) (89) (92) (81) (85) Intestine Small, Duodenum (89) (88) (92) (79) (84) Carcinoma 2 (2%) 1 (1%) 1 (1%) Polyp Adenomatous 2 (2%) 1 (1%) Intestine Small, Jejunum (89) (94) (93) (80) (85) Carcinoma 1 (1%) 1 (1%) 3 (3%) 1 (1%) Intestine Small, Ileum (91) (89) (92) (81) (84) Carcinoma 1 (1%) Liver (100) (100) (100) (98) (99) Carcinoma, Metastatic, Islets, Pancreatic 1 (1%) Carcinoma, Metastatic, Pancreas 1 (1%) Carcinoma, Metastatic, Intestine Small, Duodenum 1 (1%) Hemangiosarcoma 4 (4%) 2 (2%) 3 (3%) 5 (5%) 4 (4%) Hemangiosarcoma, Metastatic, Skin 1 (1%) Hemangiosarcoma, Metastatic, Spleen 1 (1%) 1 (1%) Hepatoblastoma 2 (2%) 2 (2%) 1 (1%) 4 (4%) 5 (5%) Hepatocellular Carcinoma 19 (19%) 14 (14%) 20 (20%) 15 (15%) 23 (23%) Hepatocellular Adenoma 28 (28%) 26 (26%) 32 (32%) 21 (21%) 30 (30%) Hepatocellular Adenoma, Multiple 2 (2%) 2 (2%) Hepatocholangiocarcinoma 1 (1%) Histiocytic Sarcoma 1 (1%) 1 (1%) 1 (1%) 1 (1%) Rhabdomyosarcoma, Metastatic, Heart 1 (1%) Page 10 NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98 Route: MAGNETIC FIELDS Time: 12:40:00 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE SHAM .02 2 GAUSS 10 10 GAUSS CONTROL GAUSS GAUSS INTER ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - cont Mesentery (13) (16) (8) (10) (9) Carcinoma, Metastatic, Islets, Pancreatic 1 (13%) Carcinoma, Metastatic, Intestine Small, Duodenum 1 (6%) Hemangiosarcoma 1 (6%) 1 (13%) Hepatocellular Carcinoma, Metastatic, Liver 1 (11%) Rhabdomyosarcoma, Metastatic, Heart 1 (13%) Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (10%) Sarcoma, Metastatic, Uncertain Primary Site 1 (10%) Oral Mucosa (2) Squamous Cell Carcinoma 1 (50%) Pancreas (99) (99) (98) (95) (98) Carcinoma 1 (1%) Carcinoma, Metastatic, Islets, Pancreatic 1 (1%) Carcinoma, Metastatic, Intestine Small, Duodenum 1 (1%) Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%) Sarcoma 1 (1%) Schwannoma Malignant, Metastatic, Skin 1 (1%) Salivary Glands (99) (99) (98) (96) (99) Stomach, Forestomach (99) (98) (97) (96) (99) Sarcoma 1 (1%) Squamous Cell Carcinoma 1 (1%) Squamous Cell Papilloma 1 (1%) Stomach, Glandular (94) (93) (97) (87) (93) Serosa, Hemangiosarcoma, Metastatic, Mesentery 1 (1%) Tongue (1) Squamous Cell Papilloma 1 (100%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Blood Vessel (97) (94) (100) (96) (98) Aorta, Adventitia, Rhabdomyosarcoma, Metastatic, Heart 1 (1%) Aorta, Adventitia, Sarcoma, Metastatic, Uncertain Primary Site 1 (1%) Heart (100) (100) (100) (99) (100) Carcinoma, Metastatic, Kidney 1 (1%) Hemangiosarcoma 2 (2%) Hemangiosarcoma, Metastatic, Liver 1 (1%) 2 (2%) 2 (2%) Hemangiosarcoma, Metastatic, Spleen 1 (1%) 1 (1%) 1 (1%) Rhabdomyosarcoma 1 (1%) 1 (1%) Sarcoma, Metastatic, Uncertain Primary Site 1 (1%) ____________________________________________________________________________________________________________________________________ Page 11 NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98 Route: MAGNETIC FIELDS Time: 12:40:00 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE SHAM .02 2 GAUSS 10 10 GAUSS CONTROL GAUSS GAUSS INTER ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (99) (96) (99) (94) (97) Adenoma 3 (3%) 1 (1%) 5 (5%) Bilateral, Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%) Capsule, Carcinoma, Metastatic, Intestine Small, Duodenum 1 (1%) Adrenal Medulla (98) (93) (99) (91) (96) Pheochromocytoma Malignant 2 (2%) Pheochromocytoma Benign 1 (1%) 1 (1%) Bilateral, Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (1%) Islets, Pancreatic (99) (99) (98) (97) (98) Adenoma 1 (1%) 3 (3%) 1 (1%) 1 (1%) Carcinoma 2 (2%) 1 (1%) 1 (1%) Hemangiosarcoma, Metastatic, Mesentery 1 (1%) Pineal Gland (55) (58) (62) (45) (57) Pituitary Gland (83) (84) (82) (84) (86) Pars Distalis, Adenoma 1 (1%) 1 (1%) Pars Intermedia, Adenoma 1 (1%) Thyroid Gland (99) (98) (98) (97) (98) Adenoma 1 (1%) 1 (1%) 1 (1%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM Tissue NOS (2) (4) (1) (1) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (50%) Histiocytic Sarcoma 1 (25%) Schwannoma Malignant 1 (100%) Pelvic, Sarcoma 1 (25%) Thoracic, Fat, Hemangioma 1 (100%) ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Epididymis (98) (99) (99) (96) (98) Carcinoma, Metastatic, Islets, Pancreatic 1 (1%) Hemangiosarcoma, Metastatic, Skin 1 (1%) Histiocytic Sarcoma 1 (1%) Bilateral, Carcinoma, Metastatic, Intestine Small, Duodenum 1 (1%) Bilateral, Sarcoma, Metastatic, Pancreas 1 (1%) Preputial Gland (98) (98) (100) (95) (99) Prostate (98) (92) (94) (94) (92) Adenoma 1 (1%) Page 12 NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98 Route: MAGNETIC FIELDS Time: 12:40:00 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE SHAM .02 2 GAUSS 10 10 GAUSS CONTROL GAUSS GAUSS INTER ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM - cont Histiocytic Sarcoma 1 (1%) Sarcoma, Metastatic, Pancreas 1 (1%) Seminal Vesicle (99) (97) (98) (98) (98) Carcinoma 1 (1%) Carcinoma, Metastatic, Islets, Pancreatic 1 (1%) Hemangiosarcoma, Metastatic, Mesentery 1 (1%) Bilateral, Sarcoma, Metastatic, Pancreas 1 (1%) Testes (99) (98) (100) (96) (98) Adenoma 1 (1%) 1 (1%) 2 (2%) 1 (1%) 1 (1%) Hemangiosarcoma 1 (1%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (99) (99) (99) (99) (100) Hemangiosarcoma, Metastatic, Liver 2 (2%) Hemangiosarcoma, Metastatic, Skin 1 (1%) Hemangiosarcoma, Metastatic, Spleen 1 (1%) 1 (1%) 1 (1%) Mast Cell Tumor Benign 1 (1%) Lymph Node (6) (6) (5) (3) (7) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (14%) Hemangiosarcoma 1 (14%) Hepatocellular Carcinoma, Metastatic, Liver 1 (14%) Histiocytic Sarcoma 1 (17%) Plasma Cell Tumor Malignant 1 (17%) Bronchial, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (20%) Lumbar, Hemangiosarcoma, Metastatic, Mesentery 1 (17%) Lumbar, Histiocytic Sarcoma 1 (33%) Lymph Node, Mandibular (92) (92) (92) (89) (90) Histiocytic Sarcoma 1 (1%) Lymph Node, Mesenteric (87) (90) (96) (85) (92) Carcinoma, Metastatic, Islets, Pancreatic 1 (1%) Carcinoma, Metastatic, Intestine Small, Duodenum 1 (1%) Histiocytic Sarcoma 1 (1%) 1 (1%) Plasma Cell Tumor Malignant 1 (1%) Rhabdomyosarcoma, Metastatic, Heart 1 (1%) 1 (1%) Sarcoma, Metastatic, Pancreas 1 (1%) Sarcoma, Metastatic, Uncertain Primary Site 1 (1%) Spleen (99) (98) (98) (93) (98) Hemangiosarcoma 2 (2%) 5 (5%) 3 (3%) 1 (1%) Hemangiosarcoma, Metastatic, Skin 1 (1%) Histiocytic Sarcoma 1 (1%) 1 (1%) Thymus (69) (68) (63) (68) (60) Page 13 NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98 Route: MAGNETIC FIELDS Time: 12:40:00 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE SHAM .02 2 GAUSS 10 10 GAUSS CONTROL GAUSS GAUSS INTER ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM - cont Sarcoma, Metastatic, Uncertain Primary Site 1 (1%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Skin (99) (99) (100) (100) (100) Carcinoma, Metastatic, Harderian Gland 1 (1%) Hemangiosarcoma 1 (1%) Histiocytic Sarcoma 1 (1%) Rhabdomyosarcoma, Metastatic, Heart 1 (1%) Sarcoma 1 (1%) Schwannoma Benign 1 (1%) Schwannoma Malignant 1 (1%) 1 (1%) Squamous Cell Papilloma 1 (1%) 1 (1%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (97) (100) (99) (99) (99) Femur, Hemangiosarcoma, Metastatic, Liver 1 (1%) Femur, Hemangiosarcoma, Metastatic, Spleen 1 (1%) Skeletal Muscle (8) (7) (2) (7) (4) Hemangiosarcoma, Metastatic, Mesentery 1 (14%) Rhabdomyosarcoma 1 (14%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (100) (99) (100) (99) (100) Meninges, Sarcoma 1 (1%) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (100) (99) (100) (99) (99) Alveolar/Bronchiolar Adenoma 24 (24%) 11 (11%) 7 (7%) 14 (14%) 13 (13%) Alveolar/Bronchiolar Adenoma, Multiple 2 (2%) 2 (2%) 2 (2%) 3 (3%) Alveolar/Bronchiolar Carcinoma 8 (8%) 11 (11%) 12 (12%) 10 (10%) 9 (9%) Alveolar/Bronchiolar Carcinoma, Multiple 1 (1%) Carcinoma, Metastatic, Harderian Gland 1 (1%) Carcinoma, Metastatic, Islets, Pancreatic 1 (1%) Carcinoma, Metastatic, Kidney 1 (1%) Carcinoma, Metastatic, Pancreas 1 (1%) Hemangiosarcoma, Metastatic, Liver 1 (1%) Hemangiosarcoma, Metastatic, Mesentery 1 (1%) Hepatoblastoma, Metastatic, Liver 1 (1%) Hepatocellular Carcinoma, Metastatic, Liver 2 (2%) 5 (5%) 8 (8%) 5 (5%) 9 (9%) Page 14 NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98 Route: MAGNETIC FIELDS Time: 12:40:00 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE SHAM .02 2 GAUSS 10 10 GAUSS CONTROL GAUSS GAUSS INTER ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM - cont Histiocytic Sarcoma 1 (1%) 1 (1%) Pheochromocytoma Malignant, Metastatic, Adrenal Medulla 1 (1%) Rhabdomyosarcoma, Metastatic, Heart 1 (1%) 1 (1%) Sarcoma, Metastatic, Uncertain Primary Site 1 (1%) 1 (1%) Schwannoma Malignant, Metastatic, Skin 1 (1%) Arteriole, Hepatoblastoma, Metastatic, Liver 1 (1%) Nose (99) (99) (100) (97) (100) Sinus, Sarcoma, Metastatic, Eye 1 (1%) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Eye (2) (2) (1) Retrobulbar, Sarcoma 1 (50%) Harderian Gland (99) (99) (100) (96) (99) Adenoma 12 (12%) 14 (14%) 16 (16%) 10 (10%) 11 (11%) Carcinoma 1 (1%) 3 (3%) Sarcoma, Metastatic, Eye 1 (1%) Bilateral, Adenoma 2 (2%) 2 (2%) Bilateral, Carcinoma 1 (1%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (99) (98) (99) (96) (97) Sarcoma, Metastatic, Pancreas 1 (1%) Bilateral, Carcinoma 1 (1%) Bilateral, Rhabdomyosarcoma, Metastatic, Heart 1 (1%) Capsule, Rhabdomyosarcoma, Metastatic, Heart 1 (1%) Cortex, Rhabdomyosarcoma, Metastatic, Heart 1 (1%) Renal Tubule, Adenoma 1 (1%) 2 (2%) Urinary Bladder (98) (95) (95) (93) (94) Histiocytic Sarcoma 1 (1%) Papilloma 1 (1%) Sarcoma, Metastatic, Pancreas 1 (1%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(100) *(100) *(100) *(100) *(100) Histiocytic Sarcoma 1 (1%) 1 (1%) 3 (3%) 1 (1%) 1 (1%) Leukemia Granulocytic 1 (1%) Lymphoma Malignant 8 (8%) 7 (7%) 4 (4%) 7 (7%) 6 (6%) Mesothelioma Malignant 2 (2%) 1 (1%) * Number of animals with any tissue examined microscopically Page 15 NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98 Route: MAGNETIC FIELDS Time: 12:40:00 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE SHAM .02 2 GAUSS 10 10 GAUSS CONTROL GAUSS GAUSS INTER ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS - cont Multiple Organs *(100) *(100) *(100) *(100) *(100) ____________________________________________________________________________________________________________________________________ Page 16 NTP Experiment-Test: 89029-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC MAGNETIC FIELDS (EMF) Date: 01/09/98 Route: MAGNETIC FIELDS Time: 12:40:00 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE SHAM .02 2 GAUSS 10 10 GAUSS CONTROL GAUSS GAUSS INTER ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 71 81 72 74 76 Total Primary Neoplasms 127 123 122 112 124 Total Animals with Benign Neoplasms 54 50 54 47 52 Total Benign Neoplasms 77 64 68 57 65 Total Animals with Malignant Neoplasms 40 49 45 49 48 Total Malignant Neoplasms 50 59 54 55 59 Total Animals with Metastatic Neoplasms 8 11 15 17 13 Total Metastatic Neoplasm 9 23 28 36 22 Total Animals with Malignant Neoplasms 1 1 Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 17 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------